Meeting
2019 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
Authors
Jacob M. Sands
Dana-Farber Cancer Institute, Boston, MA
Jacob M. Sands , Toshio Shimizu , Edward B. Garon , Jonathan Greenberg , Ferdinand M. Guevara , Rebecca Suk Heist , Fumiaki Kobayashi , Yutaka Noguchi , Daisuke Okajima , Naoyuki Tajima , Alexander I. Spira , Noboru Yamamoto , Aaron Elliott Lisberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03401385
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9051)
DOI
10.1200/JCO.2019.37.15_suppl.9051
Abstract #
9051
Poster Bd #
374
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
First Author: Jacob M. Sands
Poster
2024 ASCO Genitourinary Cancers Symposium
Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION‑PanTumor01 study.
First Author: Aaron Lisberg
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
First Author: Jordi Rodon Ahnert